These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 9050899)

  • 1. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
    Sparreboom A; van Asperen J; Mayer U; Schinkel AH; Smit JW; Meijer DK; Borst P; Nooijen WJ; Beijnen JH; van Tellingen O
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):2031-5. PubMed ID: 9050899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
    van Asperen J; Schinkel AH; Beijnen JH; Nooijen WJ; Borst P; van Tellingen O
    J Natl Cancer Inst; 1996 Jul; 88(14):994-9. PubMed ID: 8667431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
    Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
    Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.
    Smit JW; Schinkel AH; Müller M; Weert B; Meijer DK
    Hepatology; 1998 Apr; 27(4):1056-63. PubMed ID: 9537446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
    Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
    Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice.
    Oostendorp RL; Buckle T; Lambert G; Garrigue JS; Beijnen JH; Schellens JH; van Tellingen O
    Invest New Drugs; 2011 Oct; 29(5):768-76. PubMed ID: 20390333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
    Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
    Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral delivery of taxanes.
    Malingré MM; Beijnen JH; Schellens JH
    Invest New Drugs; 2001 May; 19(2):155-62. PubMed ID: 11392449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
    Smit JW; Schinkel AH; Weert B; Meijer DK
    Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
    Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms.
    Yang Z; Gao S; Wang J; Yin T; Teng Y; Wu B; You M; Jiang Z; Hu M
    Drug Metab Dispos; 2011 Oct; 39(10):1866-72. PubMed ID: 21757611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
    Yamaguchi H; Yano I; Saito H; Inui K
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1063-9. PubMed ID: 11861816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.
    Mayer U; Wagenaar E; Beijnen JH; Smit JW; Meijer DK; van Asperen J; Borst P; Schinkel AH
    Br J Pharmacol; 1996 Nov; 119(5):1038-44. PubMed ID: 8922756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
    van Asperen J; van Tellingen O; Sparreboom A; Schinkel AH; Borst P; Nooijen WJ; Beijnen JH
    Br J Cancer; 1997; 76(9):1181-3. PubMed ID: 9365166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine.
    Stephens RH; Tanianis-Hughes J; Higgs NB; Humphrey M; Warhurst G
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1095-101. PubMed ID: 12438532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.